Background Tumors of the appendicular skeleton commonly affect the proximal humerus, but there is no consensus regarding the best reconstructive technique after proximal humerus resection for tumors of the shoulder. Questions/purposes We wished to perform a systematic review to determine which surgical reconstruction offers the (1) best functional outcome as measured by the Musculoskeletal Tumor Society (MSTS) score, (2) longest construct survival, and (3) lowest complication rate after proximal humerus resection for malignant or aggressive benign tumors of the shoulder. Methods We searched the literature up to June 1, 2013, from MEDLINE, EMBASE, and the Cochrane Library. Only studies reporting results in English, Dutch, or German and with followups of 80% or more of the patients at a minimum of 2 years were included. Twenty-nine studies with 693 patients met our criteria, seven studies (24%) were level of evidence III and the remainder were level IV. Studies reported on reconstruction with prostheses (n = 17), osteoarticular allografts (n = 10), and allograftprosthesis composites (n = 11). Owing to substantial heterogeneity and bias, we narratively report our results. Results Functional scores in prosthesis studies ranged from 61% to 77% (10 studies, 141 patients), from 50% to 78% (eight studies, 84 patients) in osteoarticular graft studies, and from 57% to 91% (10 studies, 141 patients) in allograftprosthesis composite studies. Implant survival ranged from 0.38 to 1.0 in the prosthesis group (341 patients), 0.33 to 1.0 in the osteoarticular allograft group (143 patients), and 0.33 to 1.0 in allograft-prosthesis group (132 patients). Overall complications per patient varied between 0.045 and 0.85 in the prosthesis group, 0 and 1.5 in the osteoarticular graft group, and 0.19 and 0.79 in the prosthesis-composite graft group. We observed a higher fracture rate for osteoarticular allografts, but other specific complication rates were similar. Conclusions Owing to the limitations of our systematic review, we found that allograft-prosthesis composites and prostheses seem to have similar functional outcome and survival rates, and both seem to avoid fractures that are observed with osteoarticular allografts. Further collaboration in the field of surgical oncology, using randomized controlled trials, is required to establish the superiority of any particular treatment.
Introduction
The proximal humerus is the second most common site of all osseous sarcomas and the third most common site for osteosarcoma. Although osteosarcomas and Ewing's sarcomas occur characteristically in teenagers and young adults, chondrosarcomas occur in older individuals [18] . Reconstruction of the shoulder after resection of a malignant or a benign locally aggressive primary bone tumor of the proximal humerus poses the challenging problem of associated bone loss. In addition, an adequate tumor margin implies partial resection of the deltoid musculature and joint capsule and occasionally the rotator cuff, axillary nerve, glenoid, or the scapula.
There is no consensus regarding the best reconstructive technique after proximal humerus resection. Principal treatment approaches in use today include arthroplasty prostheses, osteoarticular allografts, and allograft-prosthesis composites [38, 58] . Moreover, several autologous grafts (fibula, scapular crest, or clavicle [5, 8, 47] ) have been described. Because autologous grafts often are used in conjunction with a shoulder arthrodesis, prostheses, osteoarticular allografts, and allograft-prosthesis composites are the only reconstructions allowing for a mobile glenohumeral joint. Although all of these approaches are in use, and there are some situations where only one approach might be appropriate for a particular patient, there are many scenarios in which all are potential options. However, because there are no prospective or randomized trials, it is difficult to know which approach is best in terms of functional outcome, implant survivorship, or complications.
This review aims to identify which surgical reconstruction (1) offers the best functional outcome measured by the Musculoskeletal Tumor Society (MSTS) score [20] , and (2) has the longest survival rate, and (3) lowest complication rate after proximal humerus resection for tumors of the shoulder.
Materials and Methods

Article Selection
On June 1, 2013, we searched PUBMED, EMBASE, and the Cochrane Library using the search string for title and abstract: (humerus OR shoulder OR ''upper limb'' OR ''upper extremity'') AND (neoplasm* OR tumor* OR tumour* OR malign* OR sarcoma* OR cancer*) AND (prosthe* OR autograft OR allograft OR fusion OR flail joint OR Tikhoff linberg OR arthrodesis OR clavicula pro humero OR graft OR forequarter amputation).
This search yielded 524 results from PubMed, 548 from EMBASE, and three from the Cochrane Library. Two reviewers (SAL-C, TT) independently examined the citation information for each result from the databases for relevant studies; subsequently, two independent reviewers screened the full texts (TT, SPFTN); they also scanned the reference lists of the included articles for additional studies that met the inclusion criteria ( Fig. 1 ). Inclusion criteria were determined as follows: functional outcome after proximal humerus resection for any malignant or benign locally aggressive tumor, a minimum 2-year followup, and English, Dutch, or German language publication. We excluded cohorts with less than three patients and case reports, preclinical studies, meeting abstracts, indiscernible proximal humerus patient cohorts, inadequate outcome reporting, studies with more than 20% of patients lost to followup, and salvage procedures. In case of overlapping patient cohorts [36, 48, 51, 52] , we included the study reporting on the largest cohort [36, 52] . In one of three studies [23, 37, 43] , after correspondence with the author, we included the smaller cohort with a more comprehensive functional outcome [23] .
Two independent reviewers (TT, SPFTN) critically appraised the included studies using predetermined criteria, and data were extracted with standardized sheets. Discordant judgments were resolved by consensus discussion between the two reviewers. Critical appraisal criteria included disclosure, selection of patients, outcome reporting and assessment, baseline display, and postoperative care. These criteria are based on the relevant literature [14, 28, 38, 49, 58] . Our review is registered with PROSPERO (registration number CRD42013005626) [54, 55] .
Outcome Measurements
The following data were extracted from the selected articles: author, year of publication, institute, study type, construct included, number of patients, age, followup, patients lost to followup, nature of the tumor (benign or malignant), metastasis, implant survival, complications, and MSTS score. We considered the following reconstructive techniques: prostheses, osteoarticular allografts, allograft-prosthesis composites, fibula autografts, scapular crest flaps, clavicle pro humero reconstruction, flail joint, and amputation.
Functional Outcome
In case of missing MSTS score standard deviations or baseline characteristics, we contacted the corresponding authors; of the contacted authors of 19 studies [1, 6, 9, 12, 16, 17, 19, 25, 27, 31, 36, 43, 45, 47, 50, 56, [60] [61] [62] , 13 replied [1, 6, 9, 16, 17, 27, 31, 36, 43, 45, 50, 56, 61] and seven were able to provide us with the requested additional data [6, 9, 17, 27, 36, 45, 56] . We regarded autoclaved autograft and allograft bone combined with a prosthesis as allograft-prosthesis composites. Osteoblastomas and giant cell tumors are scored as benign locally aggressive tumors with their unpredictable behavior and rare incidences of metastasis [13, 26] .
The mean MSTS score with its SD was extracted or, if appropriate, calculated from individual patient data. In two cases, scores were calculated differently: in one instance, we used the lowest possible MSTS score reflecting ''poor'', ''good'', and ''excellent'' outcomes as reported by the authors, possibly underestimating the functional results [30] . In another study we estimated the SD by computing the two and four missing values resulting in the largest SD [44] .
Implant Survival
We considered total or partial removal of the reconstruction a failure. Kaplan-Meier implant survival rates were extracted at the 5-year end point.
Complications
We evaluated the following complications: deep infections, fracture, subluxation, dislocation, proximal migration, component loosening, nonunion, and permanent nerve deficit.
Study Characteristics
Articles on amputation either focused on patient survival or included multiple disorders other than proximal humerus malignancies. No article on clavicula pro humero satisfied our inclusion criteria. Scapular crest and fibula grafts used various proximal fixation methods: plate [5, 8, 60] or wire [34] , wire and tendon [59] , suture [36] , or none at all [7, 21] . In addition, in three studies, it was reported that an allograft was used to strut the fibular grafts [7, 21, 60] , and Kumar et al. [34] reported that in one instance, an additional scapular crest graft was used. Arthoplasty prostheses, osteoarticular allografts, and allograft-prosthesis composites are comparable in the sense that they allow for reconstructions of a mobile glenohumeral joint and have similar indications, therefore only those reconstructions were included in our final analysis. Approximately 1 . 4 of the studies were level III evidence and the remainder were level IV. Critical appraisal shows only 55% of the studies reported eligibility criteria, sources, and methods of selection of participants, possibly resulting in selection bias. As only 14% reported what complications would be collected before their actual data collection and only one study used objective, independent outcome reporting, outcome bias cannot be excluded ( Fig. 2 ) (Appendix 1, Supplemental material is available with the online version of CORR). Asymmetry of the funnel plots seems to reflect the clinical and methodologic heterogeneity rather than publication bias ( Fig. 3 ) [28] .
Study Population
For this review, a total of 693 patients were included with a mean age per study ranging from 9 to 57 years. The percentage of primary malignancies varied between 23% and 100%, secondary malignancies from 0% to 77% (0% in 21 studies), and benign tumors from 0% to 75% (0% in 18 studies; Table 1 ). 
Results
MSTS Scores
Twenty-four studies reported the MSTS scores for 28 reconstructive methods for a total of 398 patients. Functional score in prosthesis studies ranged from 61% to 77% (10 studies, 141 patients); osteoarticular grafts from 50% to 78% (eight studies, 84 patients); allograft-prosthesis composites from 57% to 91% (10 studies, 141 patients; Table 2 ).
Implant Survival
Implant survival and complications were calculated for 616 patients from 29 studies. Implant survival ranged from 0.38 to 1.0 in the prosthesis group (341 patients); 0.33 to 1.0 in the osteoarticular allograft group (143 patients), and 0.33 to 1.0 in allograft-prosthesis group (132 patients; Table 3 ). 
Complications
Overall complications per patient varied between 0.045 and 0.85 in the prosthesis group, 0 and 1.5 in the osteoarticular graft group, and 0.19 and 0.79 in the prosthesis-composite graft group. In particular, the fracture rate varied among groups; proportions ranged from 0.05 to 0.17 with prostheses and 0 to 0.67 with osteoarticular grafts and composite-prosthesis allografts. However, when only including studies with more than 10 patients the fracture rates ranged from 0 to 0.05 in the prosthesis group, 0.08 to 0.62 in the osteoarticular allograft group, and 0 and 0.06 in the allograft-prosthesis composite group (Table 3) . Other complications were similar between constructs (Appendix 
Discussion
Tumors of the appendicular skeleton commonly affect the proximal humerus, and complete resection impedes shoulder function. As there is no consensus regarding the best reconstructive technique after proximal humerus resection, reviewing the literature in the absence of quality randomized prospective trials might offer some insight into the best reconstructive option. We aimed to identify which surgical reconstruction offers (1) the best functional outcome measured by the MSTS score, and (2) has the longest survival rate and (3) lowest complication rate after proximal humerus resection. Because of the limited literature available we were able to compare only arthroplasty prostheses, osteoarticular allografts, and allograft-prosthesis composites. This study has some limitations. Because this is a review of nonrandomized studies, there is an increased risk of selection bias, variation in the way in which confounding is considered in the analysis, and greater risk of other biases. All of these biases would tend to increase apparent benefits of treatments and deemphasize the problems and complications associated with these treatments. Additionally, the most commonly used score in the papers reviewed in this investigation used the MSTS score, resulting in a possibly overstated physician-perceived function, instead of a true patient-reported outcome. The MSTS score is not a validated tool and may not adequately reflect upper extremity function, as it mainly measures impairment instead of activity limitation. Moreover, the MSTS score is a physician-rated instrument and a couple studies stress its subsequent limitations [2, 53] .
Owing to the limited information reported, the current results do not allow for subgroup analysis on different clinical scenarios (eg, tumor type and stage, age, soft tissue resection, or radiographic findings). This impedes the predictive value of our results for specific patients. We include previously missing, and therefore unpublished, MSTS score standard deviations and baseline characteristics from seven studies that were not verified by peer review [6, 9, 17, 27, 36, 45, 56] .
Although allograft-prosthesis composites resulted in the largest range in MSTS scores, the majority of the scores for all three constructs were between 60% and 79%, making them seem largely comparable in functional outcome.
Implant survival looks similar between the three constructs.
The number of overall complications per patient seems greater in the osteoarticular allograft group (range, 0-1.5 versus 0.045-0.85 in the prosthesis group and 0.19-0.79 in the allograft-prosthesis composite group). The increased complication rate seems to be based on higher osteoarticular allograft fracture rates, as all other specific complications were comparable. Fracture rates between the osteoarticular allograft group and allograft-prosthesis composite group might appear similar (both 0-0.67); however, the upper limits with allograft-prosthesis composite fractures are based on relatively small studies. When comparing only studies with more than 10 patients, the allograft-prosthesis composite fracture rates (0-0.06) are comparable to those of the prosthesis (0-0.05).
Performance of a (superior) randomized controlled trial is hindered by several practical difficulties; one is the necessity of a surgeon or group of surgeons being able to confidently perform highly specialized operations such fibular transplantation, including vascular microsurgery randomized controlled trial might be difficult to conduct, several other options are available, for example, matching procedures or an expertise-based randomized trial. The latter involves a study in which patients are randomly assigned by a third party to surgeons, who then treat their patients with their preferred intervention [40] . This design prevents the exigency of different highly specialized surgeons at one institution and does not require any surgeon to abandon his or her preferred method. The limitations of the literature we surveyed suggest strongly to us that multicenter studies are warranted if we are to establish the optimal treatment for oncologic replacement of the complex shoulder. A prospective database including patients from specialized treatment centers would be an important first step. Strengths of our systematic review of the available retrospective literature were its restriction to followup of at least 2 years and restriction to studies that accounted for 80% or greater of the patients they included. Conscious of the limitations of our systematic review in coming to firm conclusions, allograft-prosthesis composites and prostheses probably are indistinguishable based on the literature, and both seem to avoid the problem of fracture that is observed with osteoarticular allografts.
